CN1227259C - 用于治疗脂代谢紊乱的与胆汁酸相连的丙醇胺类衍生物 - Google Patents

用于治疗脂代谢紊乱的与胆汁酸相连的丙醇胺类衍生物 Download PDF

Info

Publication number
CN1227259C
CN1227259C CNB998116343A CN99811634A CN1227259C CN 1227259 C CN1227259 C CN 1227259C CN B998116343 A CNB998116343 A CN B998116343A CN 99811634 A CN99811634 A CN 99811634A CN 1227259 C CN1227259 C CN 1227259C
Authority
CN
China
Prior art keywords
compounds
acid
bond
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998116343A
Other languages
English (en)
Chinese (zh)
Other versions
CN1321166A (zh
Inventor
S·斯坦格林
A·恩森
H·格罗姆毕克
W·卡拉默
E·法尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1321166A publication Critical patent/CN1321166A/zh
Application granted granted Critical
Publication of CN1227259C publication Critical patent/CN1227259C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CNB998116343A 1998-10-02 1999-09-18 用于治疗脂代谢紊乱的与胆汁酸相连的丙醇胺类衍生物 Expired - Fee Related CN1227259C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845403.1 1998-10-02
DE19845403A DE19845403B4 (de) 1998-10-02 1998-10-02 Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (2)

Publication Number Publication Date
CN1321166A CN1321166A (zh) 2001-11-07
CN1227259C true CN1227259C (zh) 2005-11-16

Family

ID=7883185

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998116343A Expired - Fee Related CN1227259C (zh) 1998-10-02 1999-09-18 用于治疗脂代谢紊乱的与胆汁酸相连的丙醇胺类衍生物

Country Status (22)

Country Link
US (1) US6180618B1 (https=)
EP (1) EP1117676B1 (https=)
JP (1) JP4598953B2 (https=)
KR (1) KR20010075511A (https=)
CN (1) CN1227259C (https=)
AR (1) AR035003A1 (https=)
AT (1) ATE273991T1 (https=)
AU (1) AU757366B2 (https=)
BR (1) BR9915019A (https=)
CA (1) CA2346085A1 (https=)
DE (2) DE19845403B4 (https=)
DK (1) DK1117676T3 (https=)
ES (1) ES2226440T3 (https=)
HK (1) HK1040717A1 (https=)
HU (1) HUP0103570A3 (https=)
ID (1) ID29353A (https=)
PL (1) PL347106A1 (https=)
PT (1) PT1117676E (https=)
RU (1) RU2234512C2 (https=)
TR (1) TR200100897T2 (https=)
WO (1) WO2000020437A1 (https=)
ZA (1) ZA200102586B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
PL3923943T3 (pl) 2019-02-12 2024-12-09 Mirum Pharmaceuticals, Inc. Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI892341A7 (fi) 1988-06-10 1989-12-11 Hoffmann La Roche Propanoliamiinijohdannaisia
GB2250634A (en) * 1990-12-04 1992-06-10 Marconi Gec Ltd Point contact diodes
NZ240846A (en) 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
JP2616845B2 (ja) * 1991-02-21 1997-06-04 清水化学株式会社 システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
DK0557879T3 (da) * 1992-02-22 1997-06-16 Hoechst Ag 4-amino-2-ureido-pyrimidin-5-carboxylsyreamider, fremgangsmåde til deres fremstilling, lægemidler med indhold af disse forbindelser og deres anvendelse
TW289021B (https=) * 1993-05-08 1996-10-21 Hoechst Ag
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
DK0869121T3 (da) * 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater

Also Published As

Publication number Publication date
HUP0103570A3 (en) 2003-01-28
DE19845403B4 (de) 2005-02-10
ID29353A (id) 2001-08-23
BR9915019A (pt) 2001-08-14
EP1117676B1 (de) 2004-08-18
DE59910300D1 (de) 2004-09-23
TR200100897T2 (tr) 2001-10-22
PT1117676E (pt) 2004-11-30
PL347106A1 (en) 2002-03-25
DK1117676T3 (da) 2004-12-20
CN1321166A (zh) 2001-11-07
EP1117676A1 (de) 2001-07-25
AR035003A1 (es) 2004-04-14
WO2000020437A1 (de) 2000-04-13
ZA200102586B (en) 2001-10-03
HUP0103570A2 (hu) 2002-02-28
JP4598953B2 (ja) 2010-12-15
RU2234512C2 (ru) 2004-08-20
ATE273991T1 (de) 2004-09-15
JP2002526550A (ja) 2002-08-20
HK1040717A1 (zh) 2002-06-21
AU6085599A (en) 2000-04-26
KR20010075511A (ko) 2001-08-09
AU757366B2 (en) 2003-02-20
US6180618B1 (en) 2001-01-30
ES2226440T3 (es) 2005-03-16
DE19845403A1 (de) 2000-04-13
CA2346085A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
CN1135223C (zh) 芳基取代的丙醇胺衍生物、包含它们的药物和它们的用途
CN1207056C (zh) 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1088456C (zh) 取代的噁唑烷需钙蛋白酶和/或组织蛋白酶b抑制剂
CN1129606C (zh) 七肽催产素类似物
CN1309711C (zh) 3－酰氨基－1,2－苯并异噁唑衍生物、其制备方法及应用
CN1040985C (zh) 苯并氮杂䓬类化合物的制备方法
CN1173951C (zh) 取代1,3-二芳基-2-吡啶-2-基-3-(吡啶-2-基氨基)-丙醇衍生物、其制备方法、含有它们的药物组合物及其应用
CN1227259C (zh) 用于治疗脂代谢紊乱的与胆汁酸相连的丙醇胺类衍生物
CN1620461A (zh) 2－氨基－丙醇衍生物
CN1060472A (zh) 三肽抗凝血酶剂
CN1131144A (zh) 甘氨酰胺衍生物及其制法和含有它们的药物
CN1040211C (zh) 基质金属蛋白酶抑制剂
CN1353701A (zh) 用作类胰蛋白酶抑制剂的肽基杂环酮类化合物
CN1127488C (zh) 具有生长激素释放特性的化合物
CN1946679A (zh) 氨基－丙醇衍生物
CN1038103A (zh) 环烷基取代的戊二酰胺利尿剂和其制备方法
CN1167710C (zh) 吡咯烷羰基氨基环状二硫化物
CN1347325A (zh) 用作生长激素促分泌剂的新酰胺衍生物
CN1135717A (zh) 抗血栓形成的氮杂环烷基链烷酰肽和假肽
CN1906207A (zh) 乙炔雌二醇的二－甾族前体药物
CN1130347C (zh) 2,3－亚甲基－氨基酸化合物,它们的制备方法和含有它们的药物组合物
CN1307588A (zh) 具有生长激素释放特性的化合物
CN1039017A (zh) 新化合物的制备方法
CN1055472C (zh) 噁唑并喹啉酮衍生物,它们的制备及其在治疗上的应用
CN1227261C (zh) 具有nk－2拮抗作用的含有四个双官能基团的单环类化合物，其制法，药物组合物及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI- AVENTIS GERMAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Frankfurt, Germany

Patentee after: Hoechst Marion Roussel de GmbH

Address before: Frankfurt, Germany

Patentee before: Awentis Medicines Deutschland GmbH

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1040717

Country of ref document: HK